Cardiovascular biomarker investigation.
Each marker is interpreted against optimal resilience thresholds — not just laboratory reference ranges. Patterns across markers are surfaced as forensic intelligence.
LDL elevation persists across consecutive panels — atherogenic burden requires lipid-pattern review.
HDL within range yet below resilience threshold — reverse cholesterol transport capacity may be reduced.
Triglyceride elevation suggests metabolic stress; investigate insulin sensitivity and post-prandial glucose handling.
Total cholesterol drift driven primarily by LDL fraction.
ApoB particle count signals atherogenic load beyond LDL concentration alone.
Non-HDL elevation captures full atherogenic lipoprotein burden.
Glycation drift below diabetic threshold but above metabolic resilience zone.
Fasting glucose entering impaired regulation zone.
Insulin elevation may precede HbA1c rise — early insulin resistance signal.
Elevated hs-CRP indicates active vascular inflammation — investigate dietary, dental, and visceral sources.
ESR drift consistent with low-grade inflammatory load.
Ferritin elevation may reflect inflammation rather than iron status.
Persistent stage 1 elevation — vascular stress signal.
Visceral adiposity correlates with metabolic & inflammatory burden.
HRV decline indicates reduced autonomic resilience.
Biomarkers are not isolated values. Atherogenic lipoprotein particles (LDL, ApoB) interact with vascular inflammation (hs-CRP) and impaired glucose handling (insulin, HbA1c) to produce a composite cardiovascular risk signature that no single reference range will surface alone.
Why ‘normal’ may not equal optimal: reference ranges describe a population, not a physiological optimum. Drift inside the range is the earliest investigative signal.